ライフサイエンスコーパス: rotavirus

1 tool specimens were collected and tested for rotavirus.

2 s and inhibits the replication of IEC-tropic rotavirus.

3 s, including influenza virus, norovirus, and rotavirus.

4 tial for the assembly of the outer capsid of rotavirus.

5 in Kilifi and Siaya; among those tested for rotavirus, 28% (315/1142) and 23% (197/877) were positiv

6 rus (n = 9), Epstein-Barr virus (n = 5), and rotavirus A (n = 3) were the most common viruses detecte

7 Rotavirus, a diarrheal pathogen spread via fecal-oral tr

8 nsight into the possible mechanisms of human rotavirus adaptation and attenuation and supports ongoin

9 ence changes in the genome that render human rotavirus adapted to growth to high levels in Vero cells

10 Rotavirus, adenovirus 40/41, and V. cholerae were the le

11 puts (ie, rotavirus disease mortality rates, rotavirus age distributions, vaccine timeliness, and vac

12 Children who were more susceptible to rotavirus also experienced higher rates of rotavirus-neg

13 entage of specimens that tested positive for rotavirus among children <5 years old hospitalized for d

14 e effectiveness against laboratory-confirmed rotavirus among children younger than 12 months old was

15 Overall, we found sustained impact on rotavirus and AGE hospitalizations and deaths.

16 ible for >=1 RV1 dose, with stool tested for rotavirus and confirmed vaccination history we compared

17 uenza, dengue fever, hepatitis C virus, HIV, rotavirus and Zika virus.

18 VP4 [P] genotype binding specificities of rotaviruses and differential expression of histo-blood g

19 need for continued monitoring of circulating rotaviruses and the effectiveness of the vaccines agains

20 95.6%, for norovirus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively.

21 d 1.2% for norovirus, sapovirus, astrovirus, rotavirus, and adenovirus, respectively.

22 scores were highest for inpatient norovirus, rotavirus, and Shigella/EIEC cases.

23 rove useful as expression vectors.IMPORTANCE Rotaviruses are a major cause of severe gastroenteritis

24 n as the viral RNA-capping enzyme.IMPORTANCE Rotaviruses are significant human pathogens that result

25 2019, in English, with laboratory-confirmed rotavirus as the endpoint.

26 Rotavirus-associated hospitalization and ED visit rates

27 We assessed RV1 effectiveness against rotavirus-associated hospitalization in Kenyan children.

28 gram provides significant protection against rotavirus-associated hospitalization which persisted bey

29 evaluate vaccine impact on the incidence of rotavirus-associated hospitalizations (RVHs).

30 Such strains will be of value in probing rotavirus biology and pathogenesis by live cell imaginin

31 Rotavirus causes severe diarrheal disease in children by

32 Rotavirus cell entry results in loss of an outer protein

33 This is the first report of a recombinant rotavirus containing a genetically engineered segment 7

34 ttributable cases of MSD and LSD were due to rotavirus, Cryptosporidium spp, enterotoxigenic Escheric

35 An accurate rotavirus diagnosis is important for clinical management

36 in preventing hospitalizations due to severe rotavirus diarrhea among infants in Zimbabwe, providing

37 We detected coinfections in cases of severe rotavirus diarrhea in a rotavirus VE trial to determine

38 c support for a concentration mechanism, but rotavirus diarrhea showed the opposite association.

39 ion and is associated with susceptibility to rotavirus diarrhea, with non-secretors less susceptible

40 ence interval [CI], 0.41-0.62) of subsequent rotavirus diarrhea.

41 avirus vaccines were effective in preventing rotavirus diarrhoea, with higher performance in countrie

42 This study describes rotavirus disease and genotypic diversity in the Austral

43 Vaccine introduction resulted in decreased rotavirus disease burden but also coincided with the eme

44 This study revealed a substantial burden of rotavirus disease in the population >=5 years of age, pa

45 d level of protection in settings where P[6] rotavirus disease is endemic, irrespective of the HBGA p

46 nce is now available for several inputs (ie, rotavirus disease mortality rates, rotavirus age distrib

47 Rotavirus disease rates dramatically declined among chil

48 Rotavirus disease was highest in children aged 5-9 years

49 1%) and 68% (95% CI, 13%-88%) against severe rotavirus disease.

50 ontribute to reduced efficacy against severe rotavirus disease.

51 tavirus seroconversion rates after the first rotavirus dose with modest or nonsignificant interferenc

52 e used to study frozen-hydrated specimens of rotavirus double-layered particles and HIV-1 virus-like

53 ine periods, the proportion of children with rotavirus dramatically declined for hospitalization (49%

54 situ cryo-electron microscopy structures of rotavirus dsRNA-dependent RNA polymerase (RdRp) in two s

55 ore sensitive probes of viral infection than rotaviruses encoding NSP1-based FPs.

56 s made at moderate levels in infected cells, rotaviruses encoding NSP3-based FPs should be more sensi

57 were observed, particularly for noroviruses, rotaviruses, enterotoxigenic Escherichia coli, and Campy

58 Thus, rotavirus exploited paracrine purinergic signaling to ge

59 The segmented 18.5-kbp dsRNA genome of rotavirus expresses 6 structural and 6 nonstructural pro

60 8 kbp and can be used to produce recombinant rotaviruses expressing a full complement of viral protei

61 The generation of recombinant rotaviruses expressing fluorescent proteins will be valu

62 ified an alternative approach for generating rotaviruses expressing FPs, one relying on fusing the re

63 nique segmented filamentous bacteria prevent rotavirus from infecting the intestinal epithelium.

64 Rotavirus G and P genotypes were assigned using reverse

65 vided near perfect protection against severe rotavirus gastroenteritis (HR, 0.04; 95% confidence inte

66 sion dramatically reduced the risk of severe rotavirus gastroenteritis (HR, 0.46; 95% CI, .25-.86).

67 00 (95% uncertainty interval 59 000-100 000) rotavirus gastroenteritis deaths (38% reduction) and cou

68 Benefit-risk ratios (rotavirus gastroenteritis deaths prevented per excess in

69 As IgA threshold increased, risk of rotavirus gastroenteritis generally decreased.

70 vaccine introduction on admissions for acute rotavirus gastroenteritis in primarily low-income and mi

71 ubstantial protection against any and severe rotavirus gastroenteritis to age 1 year.

72 s a valuable correlate of protection against rotavirus gastroenteritis to age 1 year.

73 llected from 196 children who presented with rotavirus gastroenteritis to health facilities in Blanty

74 A correlate of protection for rotavirus gastroenteritis would facilitate rapid assessm

75 level immune correlate of protection against rotavirus gastroenteritis.

76 hip between IgA thresholds and occurrence of rotavirus gastroenteritis.

77 that, through modification of segment 7, the rotavirus genome can be increased in size to at least 19

78 Notably, our work indicates that the rotavirus genome is remarkably flexible and able to acco

79 Rotavirus genome replication and assembly take place in

80 how that it is possible to modify one of the rotavirus genome segments (segment 7) such that virus ga

81 Rotavirus genotype trends were compared over time.

82 Rotavirus genotype was determined by RT-PCR.

83 We examined the trends in circulating rotavirus genotypes in Malawi over a 22-year period to a

84 The pattern and distribution of human rotavirus genotypes in young children in developing coun

85 rotavirus vaccine efficacy against emerging rotavirus genotypes.IMPORTANCE Rotavirus is an important

86 Overall, rotavirus had the highest attributable burden of diarrhe

87 The epidemiology and disease burden of rotavirus has been altered by rotavirus vaccination with

88 arrheal disease in young children, species B rotavirus has caused sporadic outbreaks of adult diarrhe

89 e groups experienced significant declines in rotavirus hospitalization rates overall; the even postva

90 ds in the epidemiology and disease burden of rotavirus hospitalizations and ED visits were examined f

91 ollowing vaccine introduction, a decrease in rotavirus hospitalizations occurred with a shift toward

92 as a median reduction of 59% (IQR, 46-74) in rotavirus hospitalizations, 36% (IQR, 23-47) in AGE hosp

93 wed published data on relative reductions of rotavirus hospitalizations, acute gastroenteritis (AGE)

94 Rotavirus ICWs were caused by the release of extracellul

95 ty and negatively associated with serum anti-rotavirus immunoglobin A.

96 nial disease pattern, sustained low rates of rotavirus in children < 3 years of age, and a shift in t

97 to determine the P and G genotypes of human rotavirus in rotavirus-positive samples.

98 Many of the sick children with G12P[8] rotavirus in their diarrheal stools also were fully vacc

99 phenotype during coinfection with wild-type rotavirus, indicating the importance of this amino acid

100 However, the underlying mechanism(s) of rotavirus-induced dysregulation remains unclear.

101 t viroplasm-associated NSP2 colocalizes with rotavirus-induced lipid droplets prior to the accumulati

102 This model of rotavirus-induced neonatal fibrosis will provide an oppo

103 nal reduced rotavirus replication, inhibited rotavirus-induced serotonin release and fluid secretion,

104 We found that rotavirus-infected cells produce paracrine signals that

105 tor that induces lipid droplet biogenesis in rotavirus-infected cells.

106 variables were significantly associated with rotavirus infection after adjusting for seasonality and

107 ified greater variation in susceptibility to rotavirus infection and RVGE in Vellore than in Mexico C

108 timate naturally-acquired protection against rotavirus infection and RVGE, and to understand how diff

109 Furthermore, rotavirus infection has been shown to modify T1D risk in

110 explained 5.9% to 6.2% of the variability in rotavirus infection in the pooled data and their predict

111 a suite of hydrometeorological variables and rotavirus infection status ascertained through community

112 Prior rotavirus infection was associated with a 50% lower haza

113 tric-scale organization of VPs formed during rotavirus infection, and quantitatively describe the str

114 virus-unvaccinated children experienced 1418 rotavirus infections and 371 episodes of RVGE over 17,63

115 iggering relationship between some wild-type rotavirus infections and T1D, but the potential effect o

116 Rotavirus infections were initially identified as possib

117 However, research into associations of rotavirus infections with T1D development in humans have

118 nt vaccines, we aim to better understand how rotavirus interacts with the host innate immune system i

119 g natural RV intestinal infection.IMPORTANCE Rotavirus is a highly infectious pathogen that causes se

120 Rotavirus is a leading cause of mortality among children

121 Rotavirus is a major cause of gastroenteritis in childre

122 inst emerging rotavirus genotypes.IMPORTANCE Rotavirus is an important cause of childhood diarrheal d

123 Rotavirus is an important cause of diarrheal disease in

124 and pathogenesis.IMPORTANCE While species A rotavirus is commonly associated with diarrheal disease

125 While susceptibility of children to rotavirus is known to vary within and between settings,

126 Rotavirus is the leading global cause of diarrheal morta

127 Rotaviruses, like other non-enveloped, double-strand RNA

128 t contain <2 x 10(-6) focus-forming units of rotavirus, <1 x 10(-4) CFU of Vibrio cholerae, and <9 x

129 Recombinant rotaviruses made with the modified pT7/NSP3 vectors were

130 iated membranes, providing evidence that the rotavirus maturation process of "budding" occurs through

131 Changing the paradigm for rotavirus maturation, we propose that the cellular membr

132 influenzae type b, Streptococcus pneumoniae, rotavirus, measles, meningitis A, rubella, and yellow fe

133 coverage among rotavirus positive (cases) vs rotavirus negative (controls) using multivariable logist

134 RVH pre- and post-vaccine introduction using rotavirus-negative cases as a control series.

135 cluded 903 rotavirus-positive cases and 2685 rotavirus-negative controls in the analysis; 99% had ver

136 o rotavirus also experienced higher rates of rotavirus-negative diarrhea, and higher risk of moderate

137 Recombinant rotavirus NSP2 S313D (rRV NSP2 S313D) is significantly d

138 t hospitalization or treatment in A&E due to rotavirus of any severity was 61% (95% confidence interv

139 dy of research on the potential influence of rotavirus on T1D.

140 In Tunisia, we observed that rotavirus P[8]-3 and P[4] strains in young children with

141 the cellular membranes required for immature rotavirus particle budding are not an extension of the E

142 ation history we compared RV1 coverage among rotavirus positive (cases) vs rotavirus negative (contro

143 Rotavirus positive faecal samples were collected from la

144 strains pre- and post-vaccine introduction, rotavirus positive fecal samples collected between 2011

145 Among 677 eligible children, 110 (16%) were rotavirus positive.

146 tries with very high child mortality, 69% of rotavirus-positive admissions in children <5 years of ag

147 We included 903 rotavirus-positive cases and 2685 rotavirus-negative con

148 Bacterial coinfections in rotavirus-positive diarrhea were associated with a longe

149 Between 2016-2018, rotavirus-positive results in our laboratory were from v

150 nel followed by genotyping of norovirus- and rotavirus-positive samples.

151 the P and G genotypes of human rotavirus in rotavirus-positive samples.

152 ber of enrolled infants, and case counts for rotavirus-positive severe gastroenteritis in both non-va

153 Data on rotavirus-positive stool specimens among children age <5

154 observing the intracellular distribution of rotavirus proteins and their organization in VPs have la

155 droplets prior to the accumulation of other rotavirus proteins that are required for viroplasm forma

156 n the postvaccine era, a biennial pattern of rotavirus rates was observed, with a trend toward an old

157 Thus, in this study we generated an RRV-TUCH rotavirus reassortant (designated as T(R(VP2,VP4)) ) tha

158 Rotavirus remains a leading cause of pediatric diarrheal

159 t proteins will be valuable for the study of rotavirus replication and pathogenesis by live cell imag

160 hance the understanding of a key step of the rotavirus replication cycle.

161 nterferon-activated RNase L signaling blocks rotavirus replication in a strain-specific manner.

162 ut not hamster cells, and enhances species A rotavirus replication in culture.

163 Blocking the ADP signal reduced rotavirus replication, inhibited rotavirus-induced serot

164 in neonatal mouse IECs and does not inhibit rotavirus replication.

165 f using the recently developed plasmid-based rotavirus reverse genetics (RG) system to generate recom

166 In the murine model of BA, rhesus rotavirus (RRV) infection of newborn pups results in a c

167 ion fetuses proved to be resistant to rhesus rotavirus (RRV) mediated liver inflammation.

168 Rhesus rotavirus (RRV)-mediated experimental BA was induced in

169 enerate and characterize several recombinant rotaviruses (rRVs) with mutations in NSP5.

170 actories in other RNA viruses.IMPORTANCE The rotavirus (RV) double-stranded RNA genome is replicated

171 es from humans or animals.IMPORTANCE Group A rotavirus (RV) remains as the single most important caus

172 Rotavirus (RV) replicates in round-shaped cytoplasmic vi

173 Rotavirus (RV) replication in viroplasms requires intera

174 Our understanding of how rotavirus (RV) subverts host innate immune signaling has

175 etics (RG) system was recently developed for rotavirus (RV), opening new avenues for in-depth molecul

176 Rotaviruses (RV) cause acute severe diarrhea in the abse

177 when compared with globally selected group A rotavirus (RVA) G1P[8] reference strains.

178 viral genome replication.IMPORTANCE Group A rotaviruses (RVAs) are widespread in nature, infecting n

179 Rotavirus samples were genotyped using a hemi-nested mul

180 economic factors on the spatial variation of rotavirus seasonality remains unclear.

181 nt study, we analyzed their association with rotavirus seasonality, specifically the odds of monsoon

182 oped that allows genetic manipulation of the rotavirus segmented double-stranded RNA genome.

183 oncomitantly with rotavirus vaccine, reduces rotavirus seroconversion rates after the first rotavirus

184 High and persistent rotavirus shedding among vaccinated children with breakt

185 Quantifying rotavirus shedding among vaccinated individuals will aid

186 In neonatal rats, CDC-9 P45 showed reduced rotavirus shedding in fecal specimens and did not induce

187 similar aetiologies, interventions targeting rotavirus, Shigella spp, enterotoxigenic E coli producin

188 Rotavirus species B (RVB) has been associated with spora

189 rus vaccine (RotarixTM) trial in Bangladesh, rotavirus-specific plasma IgA antibody seroconversion ra

190 Rotavirus strain diversity and genotype variation in Mal

191 A rich rotavirus strain diversity circulated throughout the 22-

192 ponse of a wild-type and an attenuated human rotavirus strain, CDC-9, in Caco-2 cells and neonatal ra

193 where the Lewis-negative phenotype and P[6] rotavirus strains are common.

194 This study highlights the continued need for rotavirus surveillance across the population, despite th

195 ears of data from the WHO-coordinated Global Rotavirus Surveillance Network (GRSN).

196 stralia-wide participating in the Australian Rotavirus Surveillance Program between 2010 and 2018.

197 in 71/152 (46.7%) infants with a request for rotavirus testing.

198 TANCE Previous studies generated recombinant rotaviruses that express FPs by inserting reporter genes

199 s approach, we have generated wild-type-like rotaviruses that express various fluorescent reporter pr

200 esults suggest that the effect of climate on rotavirus transmission was mediated by four independent

201 Cumulatively, 573 rotavirus-unvaccinated children experienced 1418 rotavir

202 Efforts to improve rotavirus uptake and nutritional status are important to

203 ies in Blantyre, Malawi, and were tested for rotavirus using a VP6 semi-quantitative, real-time polym

204 re studies have shown an association between rotavirus vaccination and intussusception.

205 ghtly increased risk of intussusception with rotavirus vaccination has been found.

206 te ratios within 1-7, 8-21, and 1-21 days of rotavirus vaccination in children aged 28-275 days at on

207 Rotavirus vaccination may be the first practical measure

208 reases, recent studies have assessed whether rotavirus vaccination modifies T1D development, finding

209 ections and T1D, but the potential effect of rotavirus vaccination remains unclear.

210 essing the potential benefits of alternative rotavirus vaccination schedules in different countries a

211 Previous studies have found rotavirus vaccination to be highly cost-effective in low

212 mation of intussusception were enrolled, and rotavirus vaccination was ascertained by means of vaccin

213 ease burden of rotavirus has been altered by rotavirus vaccination with a biennial disease pattern, s

214 me since administration of the final dose of rotavirus vaccination), the number of enrolled infants,

215 Despite rotavirus vaccination, diarrhea remains a leading cause

216 ading to intussusception, particularly after rotavirus vaccination.

217 Rotavirus vaccine (Rotarix(R), RV1) has reduced diarrhea

218 In a monovalent G1P[8] rotavirus vaccine (RotarixTM) trial in Bangladesh, rotav

219 A three-dose, oral rotavirus vaccine (Rotavac) was introduced in the univer

220 Kenya introduced monovalent rotavirus vaccine (RV1) in July 2014.

221 e association between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a ph

222 ssed for oral poliovirus vaccine (OPV), oral rotavirus vaccine (RVV), oral cholera vaccine (OCV), and

223 type distribution were observed based on the rotavirus vaccine administered to infants <1 year of age

224 nt interference after completion of the full rotavirus vaccine course.

225 he 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the

226 of targeted attenuation for next-generation rotavirus vaccine design.

227 6 Ghanaian infants after 2-3 doses of G1P[8] rotavirus vaccine during a vaccine trial, by HBGA status

228 Data on rotavirus vaccine effectiveness in sub-Saharan Africa ar

229 phasize the need for continued monitoring of rotavirus vaccine efficacy against emerging rotavirus ge

230 orts to develop CDC-9 as a new generation of rotavirus vaccine for live oral or parenteral administra

231 h both their first and their second doses of rotavirus vaccine had 0.63 times the odds of seroconvert

232 ding concomitant receipt of OPV, that affect rotavirus vaccine immunogenicity in high- and low-child-

233 concomitantly with rotavirus vaccine reduced rotavirus vaccine immunogenicity.

234 should encourage countries still considering rotavirus vaccine implementation.

235 In countries that had not introduced rotavirus vaccine in their national immunisation program

236 006, more than 100 countries have introduced rotavirus vaccine into their immunization programs.

237 zed for diarrhea was 40% (IQR, 28-45) before rotavirus vaccine introduction and 20% (IQR, 20-20) 4 ye

238 We describe the impact of rotavirus vaccine introduction on admissions for acute r

239 dditional evidence for countries considering rotavirus vaccine introduction that live, oral rotavirus

240 at least 12 months of data before and after rotavirus vaccine introduction were included.

241 ectious etiologies of intussusception before rotavirus vaccine introduction.

242 Monovalent rotavirus vaccine is effective in preventing hospitaliza

243 Likelihood of "take" for any particular rotavirus vaccine may differ across populations based on

244 vides an informative threshold for assessing rotavirus vaccine performance.

245 The rotavirus vaccine produced in India that we evaluated wa

246 was that OPV administered concomitantly with rotavirus vaccine reduced rotavirus vaccine immunogenici

247 milk secretor status on oral live-attenuated rotavirus vaccine response in breastfed infants has not

248 should be considered when interpreting oral rotavirus vaccine responses in low- and middle-income se

249 ographic characteristics, symptom onset, and rotavirus vaccine status were ascertained.

250 We prepared a human rotavirus vaccine strain, CDC-9 (G1P[8]), which when gro

251 Horizontal transmission of rotavirus vaccine virus may contribute to indirect effec

252 ned among children <5 years of age since the rotavirus vaccine was introduced in 2006; population-lev

253 doses would be given; the first dose of the rotavirus vaccine would be co-administered with either B

254 virus may contribute to indirect effects of rotavirus vaccine, but data are lacking from low-income

255 (OPV), when administered concomitantly with rotavirus vaccine, reduces rotavirus seroconversion rate

256 Monovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introd

257 in pathogens following the introduction of a rotavirus vaccine.

258 ing a strategy for the development of future rotavirus vaccine.

259 tavirus vaccine introduction that live, oral rotavirus vaccines are effective in high-child-mortality

260 anisms for the adaptation and attenuation of rotavirus vaccines are not fully understood.

261 adaptation and in vivo attenuation of human rotavirus vaccines are not known.

262 occal conjugate vaccines and live attenuated rotavirus vaccines confer 19.7% (95% confidence interval

263 P[6]-based rotavirus vaccines could broaden protection in such sett

264 Rotavirus vaccines have a favourable benefit-risk profil

265 Live oral rotavirus vaccines have been developed by serial passagi

266 Since licensure in 2006, rotavirus vaccines have been introduced in more than 100

267 cine efficacy by duration of follow-up), new rotavirus vaccines have entered the market, vaccine pric

268 Infant rotavirus vaccines have led to substantial reductions in

269 Rotavirus vaccines have suboptimal efficacy in low- to m

270 re to assess the real-world effectiveness of rotavirus vaccines in a range of settings.

271 l evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab

272 bout the new introduction and current use of rotavirus vaccines in Gavi countries.

273 As global availability of rotavirus vaccines increases, recent studies have assess

274 The efficacy of rotavirus vaccines is variable in settings with differen

275 er current coverage levels, pneumococcal and rotavirus vaccines prevent 23.8 million and 13.6 million

276 entified all randomised controlled trials of rotavirus vaccines published until April 4, 2018, using

277 d be similar to the risk seen with different rotavirus vaccines used in other countries.

278 The duration of protection offered by rotavirus vaccines varies across the world, and this var

279 Rotavirus vaccines were effective in preventing rotaviru

280 Studies of other infant rotavirus vaccines were excluded because little or no po

281 oduction, impact and further developments of rotavirus vaccines were reviewed.

282 niversal childhood vaccines (eg, measles and rotavirus vaccines).

283 ded observational, post-licensure studies of rotavirus vaccines, published from Jan 1, 2006, to Dec 3

284 nation strategies and the next generation of rotavirus vaccines.

285 determine whether these negatively impacted rotavirus VE estimates.

286 uld explain an important fraction of the low rotavirus VE in this setting.

287 s in cases of severe rotavirus diarrhea in a rotavirus VE trial to determine whether these negatively

288 and estimated the impact of coinfections on rotavirus VE using a test-negative design.

289 termined a high-resolution structure for the rotavirus VP1 RdRp in situ, by local reconstruction of d

290 Two immunodominant proteins of rotavirus, VP7 and VP4, determine G and P genotypes, res

291 ears for LSD versus MSD, by age stratum, for rotavirus was 22.3 versus 5.5 (0-11 months), 9.8 versus

292 s in those that have introduced the vaccine, rotavirus was detected in 23.0% (0.7-57.7) of admissions

293 e in their national immunisation programmes, rotavirus was detected in 38.0% (95% CI 4.8-73.4) of adm

294 Rotavirus was detected in 39 specimens (11.17%) by PAGE

295 Wild-type rotavirus was not associated with intussusception (OR, 1

296 Rotavirus was the leading cause of severe diarrhea even

297 Rotavirus was the leading pathogen in children under 5 y

298 esis by live cell imagining and suggest that rotaviruses will prove useful as expression vectors.IMPO

299 Using reverse genetics, we generated a rotavirus with a phosphomimetic NSP2 (S313D) mutation to

300 genetics was used to generate a recombinant rotavirus with a single phosphomimetic mutation in nonst